24,140 Shares in Omnicell, Inc. $OMCL Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 24,140 shares of the company’s stock, valued at approximately $1,002,000. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.05% of Omnicell as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Dana Investment Advisors Inc. purchased a new position in shares of Omnicell during the fourth quarter valued at $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in Omnicell by 71.1% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock worth $6,343,000 after acquiring an additional 58,193 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in Omnicell by 96.3% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company’s stock worth $1,174,000 after acquiring an additional 12,713 shares during the period. Peregrine Capital Management LLC acquired a new stake in Omnicell during the 4th quarter worth about $4,804,000. Finally, Bank of America Corp DE grew its stake in Omnicell by 31.3% during the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after acquiring an additional 138,537 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

Shares of OMCL stock opened at $35.58 on Friday. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The stock’s 50-day moving average is $40.38 and its two-hundred day moving average is $39.68. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The firm has a market cap of $1.62 billion, a P/E ratio of 42.36, a PEG ratio of 0.89 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same quarter in the previous year, the business posted $0.45 EPS. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts predict that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. KeyCorp decreased their price target on shares of Omnicell from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Craig Hallum reiterated a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company cut their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.